tiprankstipranks
Advertisement
Advertisement

CH:IDIA Stock Latest News

RatingsBuy Rating Reaffirmed on Daridorexant Growth Prospects; 12‑Month Price Target Maintained at $5
5d ago
Idorsia: Positive Pediatric Daridorexant Data and Neurodevelopmental Expansion Drive Buy Rating and CHF5 Target
PremiumRatings
Idorsia: Positive Pediatric Daridorexant Data and Neurodevelopmental Expansion Drive Buy Rating and CHF5 Target
2M ago
Idorsia: Leadership Reset and Pipeline Expansion Underpin Buy Rating and CHF5 Price Target
PremiumRatings
Idorsia: Leadership Reset and Pipeline Expansion Underpin Buy Rating and CHF5 Price Target
2M ago
Idorsia: Expanding QUVIVIQ Footprint and Aprocitentan Upside Support Buy Rating Despite Lowered Target
PremiumRatings
Idorsia: Expanding QUVIVIQ Footprint and Aprocitentan Upside Support Buy Rating Despite Lowered Target
3M ago
Idorsia price target lowered to CHF 5 from CHF 6 at H.C. Wainwright
PremiumThe Fly
Idorsia price target lowered to CHF 5 from CHF 6 at H.C. Wainwright
3M ago
Idorsia Earnings Call Signals Turnaround, Risks Linger
PremiumCompany AnnouncementsIdorsia Earnings Call Signals Turnaround, Risks Linger
3M ago
Idorsia: FDA-Aligned Phase 3 Pathway and Broad Fabry Disease Positioning Support Buy Rating and CHF6 Target
Premium
Ratings
Idorsia: FDA-Aligned Phase 3 Pathway and Broad Fabry Disease Positioning Support Buy Rating and CHF6 Target
4M ago
Idorsia: Latin America QUVIVIQ Deal and Pipeline Optionality De‑Risk Path to Profitability, Supporting Reiterated Buy Rating
Premium
Ratings
Idorsia: Latin America QUVIVIQ Deal and Pipeline Optionality De‑Risk Path to Profitability, Supporting Reiterated Buy Rating
4M ago
Idorsia: Differentiated Insomnia and Hypertension Assets, Understated Guidance, and Pipeline Upside Support Reiterated Buy Rating
PremiumRatings
Idorsia: Differentiated Insomnia and Hypertension Assets, Understated Guidance, and Pipeline Upside Support Reiterated Buy Rating
4M ago
PremiumRatings
Idorsia: Cardiovascular Franchise Momentum and Underappreciated Pipeline Drive Buy Rating and Valuation Upside
5M ago
Buy Rating for Idorsia Driven by Promising Aprocitentan Trial Results and Market Potential
PremiumRatings
Buy Rating for Idorsia Driven by Promising Aprocitentan Trial Results and Market Potential
6M ago
Idorsia upgraded to Buy from Hold at Kepler Cheuvreux
PremiumThe Fly
Idorsia upgraded to Buy from Hold at Kepler Cheuvreux
6M ago
Idorsia Ltd’s Strengthened Financial Position and Growth Prospects Justify Buy Rating
PremiumRatingsIdorsia Ltd’s Strengthened Financial Position and Growth Prospects Justify Buy Rating
7M ago
Idorsia’s Growth Potential Bolstered by Aprocitentan Approval and Strategic Commercialization Efforts
Premium
Ratings
Idorsia’s Growth Potential Bolstered by Aprocitentan Approval and Strategic Commercialization Efforts
8M ago
Idorsia upgraded to Buy from Neutral at H.C. Wainwright
Premium
The Fly
Idorsia upgraded to Buy from Neutral at H.C. Wainwright
9M ago
Idorsia price target raised to CHF 2 from CHF 1 at Deutsche Bank
PremiumThe Fly
Idorsia price target raised to CHF 2 from CHF 1 at Deutsche Bank
9M ago
Idorsia Ltd Earnings Call: Strong Growth Amid Challenges
PremiumCompany Announcements
Idorsia Ltd Earnings Call: Strong Growth Amid Challenges
10M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >